In contrast, inactivating p16Ink4A/p19Arf is probably necessary in KrasG12D-induced tumors to overcome the checkpoints induced by these tumor suppressors and the senescence barrier imposed by the p16Ink4A-Rb pathway21. The gene discussed is CDKN2A; the disease is neoplasm.